Evidence map›Paper›PMID 39922815›Full record

ArticleNPJ breast cancer2025

Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.

Regina Peña-Enríquez, Begoña Bermejo, Marina Pollán, Alejandra Díaz-Chacón, Yolanda Jerez Gilarranz, José J Ponce Lorenzo, Antonio Fernández Aramburo, Blanca Cantos Sánchez de Ibargüen, Ana Santaballa Bertrán, Elena Galve-Calvo and 15 more

Abstract read
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Postpartum breast cancer: evidence for a distinct phenotype.Journal of the National Cancer Institute · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Regina Peña-EnríquezInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.ORCID http://orcid.org/0009-0004-7356-2781
Begoña BermejoGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Marina PollánGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Alejandra Díaz-ChacónInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.
Yolanda Jerez GilarranzGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
José J Ponce LorenzoGEICAM, Spanish Breast Cancer Group, Madrid, Spain.ORCID http://orcid.org/0000-0002-0491-901X
Antonio Fernández AramburoGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Blanca Cantos Sánchez de IbargüenGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Ana Santaballa BertránGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Elena Galve-CalvoGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Álvaro Jiménez-ArranzInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.
Yolanda FernándezGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
María Eva PérezGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Susana De La CruzGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Antonio Anton-TorresGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Fernando MorenoGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
María Jesús Vidal-LosadaGEICAM, Spanish Breast Cancer Group, Madrid, Spain.ORCID http://orcid.org/0000-0003-1992-5727
María Helena López-CeballosGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Isabel BlancasGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
María José EcharriGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Raúl RincónGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Rosalía CaballeroGEICAM, Spanish Breast Cancer Group, Madrid, Spain.ORCID http://orcid.org/0000-0002-6027-1748
Ángel Guerrero-ZotanoGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
Silvia Guil-LunaInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain. v22gulus@uco.es.
Juan de la Haba-RodríguezInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain. juahaba@gmail.com.

Funding

Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI18/00817Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI22/00969
6 · The paper itself

Abstract

Pregnancy-associated breast cancer (PABC), diagnosed during or shortly after pregnancy, is a challenging entity with an aggressive biology and poor prognosis. This study analyzed the clinicopathological characteristics and gene expression profile of 33 PABC and 26 non-PABC patients using the nCounter BC360 Panel (NanoString). Notably, PABC showed a higher prevalence of basal-like tumors than non-PABC (48.48% vs 15.38%, p = 0.012) and displayed 73 differentially expressed genes (e.g., DEPDC1, CCNA2, PSAT1, CDKN3, and FAM83D), enriched in DNA repair and cell proliferation pathways. Through the PPI network, we also identified a cluster of cell-cycle regulation genes like MYC, FOXM1, or PTEN. Interestingly, differences emerged when comparing patients diagnosed during gestation (PABC-GS) and the postpartum period (PABC-PP), with PABC-PP showing increased expression of immune-related genes, including PD-1, and greater immune cell infiltration (Tregs, macrophages, neutrophils, B-cells). These findings suggest an enhanced proliferative capacity and impaired DNA repair in PABC, and underscore the role of immune infiltration in postpartum cases; providing insights into its aggressive nature and potential targets.

Identifiers

PMID39922815
PMCPMC11807221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.